vs
Apellis Pharmaceuticals, Inc.（APLS）与null（SDHC）财务数据对比。点击上方公司名可切换其他公司
null的季度营收约是Apellis Pharmaceuticals, Inc.的1.3倍（$260.4M vs $199.9M），null净利率更高（1.4% vs -29.5%，领先30.8%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -9.4%），null自由现金流更多（$8.7M vs $-14.3M），过去两年null的营收复合增速更高（17.3% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
史密斯韦森品牌公司是美国的枪械制造商，总部位于美国田纳西州玛丽维尔，是该领域历史悠久且知名的生产企业，在民用及警用枪械市场拥有较高的认可度。
APLS vs SDHC — 直观对比
营收规模更大
SDHC
是对方的1.3倍
$199.9M
营收增速更快
APLS
高出3.5%
-9.4%
净利率更高
SDHC
高出30.8%
-29.5%
自由现金流更多
SDHC
多$23.0M
$-14.3M
两年增速更快
SDHC
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $260.4M |
| 净利润 | $-59.0M | $3.5M |
| 毛利率 | — | 19.9% |
| 营业利润率 | -25.6% | 6.5% |
| 净利率 | -29.5% | 1.4% |
| 营收同比 | -5.9% | -9.4% |
| 净利润同比 | -62.2% | -14.3% |
| 每股收益（稀释后） | $-0.40 | $0.39 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSSDHC
| Q4 25 | $199.9M | $260.4M | ||
| Q3 25 | $458.6M | $262.0M | ||
| Q2 25 | $178.5M | $223.9M | ||
| Q1 25 | $166.8M | $224.7M | ||
| Q4 24 | $212.5M | $287.5M | ||
| Q3 24 | $196.8M | $277.8M | ||
| Q2 24 | $199.7M | $220.9M | ||
| Q1 24 | $172.3M | $189.2M |
净利润APLSSDHC
| Q4 25 | $-59.0M | $3.5M | ||
| Q3 25 | $215.7M | $2.1M | ||
| Q2 25 | $-42.2M | $2.4M | ||
| Q1 25 | $-92.2M | $2.7M | ||
| Q4 24 | $-36.4M | $4.1M | ||
| Q3 24 | $-57.4M | $5.3M | ||
| Q2 24 | $-37.7M | $3.6M | ||
| Q1 24 | $-66.4M | $3.0M |
毛利率APLSSDHC
| Q4 25 | — | 19.9% | ||
| Q3 25 | — | 21.0% | ||
| Q2 25 | — | 23.2% | ||
| Q1 25 | — | 23.8% | ||
| Q4 24 | — | 25.5% | ||
| Q3 24 | — | 26.5% | ||
| Q2 24 | — | 26.7% | ||
| Q1 24 | — | 26.1% |
营业利润率APLSSDHC
| Q4 25 | -25.6% | 6.5% | ||
| Q3 25 | 48.7% | 6.6% | ||
| Q2 25 | -18.6% | 7.7% | ||
| Q1 25 | -50.0% | 8.7% | ||
| Q4 24 | -12.3% | 10.4% | ||
| Q3 24 | -24.0% | 14.2% | ||
| Q2 24 | -14.7% | 11.7% | ||
| Q1 24 | -36.0% | 11.3% |
净利率APLSSDHC
| Q4 25 | -29.5% | 1.4% | ||
| Q3 25 | 47.0% | 0.8% | ||
| Q2 25 | -23.6% | 1.1% | ||
| Q1 25 | -55.3% | 1.2% | ||
| Q4 24 | -17.1% | 1.4% | ||
| Q3 24 | -29.2% | 1.9% | ||
| Q2 24 | -18.9% | 1.7% | ||
| Q1 24 | -38.5% | 1.6% |
每股收益（稀释后）APLSSDHC
| Q4 25 | $-0.40 | $0.39 | ||
| Q3 25 | $1.67 | $0.24 | ||
| Q2 25 | $-0.33 | $0.26 | ||
| Q1 25 | $-0.74 | $0.30 | ||
| Q4 24 | $-0.30 | $0.50 | ||
| Q3 24 | $-0.46 | $0.58 | ||
| Q2 24 | $-0.30 | $0.40 | ||
| Q1 24 | $-0.54 | $0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $12.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $86.7M |
| 总资产 | $1.1B | $557.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSSDHC
| Q4 25 | $466.2M | $12.7M | ||
| Q3 25 | $479.2M | $14.8M | ||
| Q2 25 | $370.0M | $16.8M | ||
| Q1 25 | $358.4M | $12.7M | ||
| Q4 24 | $411.3M | $22.4M | ||
| Q3 24 | $396.9M | $23.7M | ||
| Q2 24 | $360.1M | $17.3M | ||
| Q1 24 | $325.9M | $32.8M |
总债务APLSSDHC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSSDHC
| Q4 25 | $370.1M | $86.7M | ||
| Q3 25 | $401.2M | $82.2M | ||
| Q2 25 | $156.3M | $80.0M | ||
| Q1 25 | $164.2M | $76.9M | ||
| Q4 24 | $228.5M | $73.6M | ||
| Q3 24 | $237.1M | $68.4M | ||
| Q2 24 | $264.3M | $62.1M | ||
| Q1 24 | $266.7M | $59.7M |
总资产APLSSDHC
| Q4 25 | $1.1B | $557.6M | ||
| Q3 25 | $1.1B | $571.6M | ||
| Q2 25 | $821.4M | $570.2M | ||
| Q1 25 | $807.3M | $513.9M | ||
| Q4 24 | $885.1M | $475.9M | ||
| Q3 24 | $901.9M | $460.1M | ||
| Q2 24 | $904.5M | $429.3M | ||
| Q1 24 | $831.9M | $401.3M |
负债/权益比APLSSDHC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $9.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $8.7M |
| 自由现金流率自由现金流/营收 | -7.1% | 3.4% |
| 资本支出强度资本支出/营收 | 0.1% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 2.77× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-36.9M |
8季度趋势，按日历期对齐
经营现金流APLSSDHC
| Q4 25 | $-14.2M | $9.8M | ||
| Q3 25 | $108.5M | $22.8M | ||
| Q2 25 | $4.4M | $-28.9M | ||
| Q1 25 | $-53.4M | $-34.9M | ||
| Q4 24 | $19.4M | $5.5M | ||
| Q3 24 | $34.1M | $22.9M | ||
| Q2 24 | $-8.3M | $39.0K | ||
| Q1 24 | $-133.0M | $-9.3M |
自由现金流APLSSDHC
| Q4 25 | $-14.3M | $8.7M | ||
| Q3 25 | $108.3M | $21.4M | ||
| Q2 25 | $4.4M | $-31.1M | ||
| Q1 25 | $-53.4M | $-35.9M | ||
| Q4 24 | $19.3M | $4.8M | ||
| Q3 24 | — | $22.3M | ||
| Q2 24 | $-8.4M | $-2.1M | ||
| Q1 24 | $-133.3M | $-9.7M |
自由现金流率APLSSDHC
| Q4 25 | -7.1% | 3.4% | ||
| Q3 25 | 23.6% | 8.2% | ||
| Q2 25 | 2.5% | -13.9% | ||
| Q1 25 | -32.0% | -16.0% | ||
| Q4 24 | 9.1% | 1.7% | ||
| Q3 24 | — | 8.0% | ||
| Q2 24 | -4.2% | -1.0% | ||
| Q1 24 | -77.3% | -5.1% |
资本支出强度APLSSDHC
| Q4 25 | 0.1% | 0.4% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.0% | 0.9% | ||
| Q1 25 | 0.0% | 0.5% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | 0.0% | 1.0% | ||
| Q1 24 | 0.2% | 0.2% |
现金转化率APLSSDHC
| Q4 25 | — | 2.77× | ||
| Q3 25 | 0.50× | 10.70× | ||
| Q2 25 | — | -12.24× | ||
| Q1 25 | — | -13.01× | ||
| Q4 24 | — | 1.33× | ||
| Q3 24 | — | 4.28× | ||
| Q2 24 | — | 0.01× | ||
| Q1 24 | — | -3.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SDHC
| Southeast | $164.7M | 63% |
| Central | $95.8M | 37% |
